The FDA approved AbbVie’s Juvmo (tavapadon), an oral selective D1/D5 receptor agonist, as a new Parkinson’s disease treatment option. Juvmo is described as first-in-class for its receptor selectivity profile and is intended for adult patients with Parkinson’s, with or without concurrent levodopa therapy. The approval reflects how receptor-specific dopaminergic approaches are expanding beyond levodopa-based regimens. AbbVie expects availability next month, which will determine how quickly clinicians and payers can integrate the therapy. For the market, Juvmo’s differentiation will likely be evaluated against existing symptomatic options in terms of efficacy, tolerability, and whether it reduces fluctuations when used alongside levodopa. The approval also adds commercial momentum for AbbVie’s neurology portfolio after its acquisition of Cerevel Therapeutics in 2024, positioning Juvmo as the first major label expansion tied to the acquired assets.